Circulating cell-free DNA (ccfDNA) has emerged as a promising diagnostic tool in oncology.
Identification of tumour-derived ccfDNA (ie circulating tumour DNA [ctDNA]) provides non …

Pancreatic cancer usually results in poor survival with limited options for treatment, as most
affected individuals present with advanced disease. Early detection of preinvasive …

Currently, checkpoint inhibitor‐based immunotherapy has emerged as prevailing treatment
modality for diverse cancers. However, immunotherapy as a first‐line therapy has not …

Background KRAS circulating tumor DNA (ctDNA) has shown biomarker potential for
pancreatic ductal adenocarcinoma (PDAC) but has not been applied in clinical routine yet …

Introduction Most patients with pancreatic cancer present with advanced stage, incurable
disease. However, patients with high-grade precancerous lesions and many patients with …

In recent years, cancer genomic medicine centered on comprehensive genome profile
(CGP) analysis has become widely used in the field of pancreatic cancer. Endoscopic …

The publication of the “Pan-Cancer Atlas” by the Pan-Cancer Analysis of Whole Genomes
Consortium, a partnership formed by The Cancer Genome Atlas (TCGA) and International …

Simple Summary Pancreatic cancer and cholangiocarcinoma are aggressive diseases
mostly diagnosed at an advanced and inoperable stage. This review presents the value of …

Abstract Background Circulating tumor DNA (ctDNA) is a promising biomarker for early
tumor detection and minimal residual disease (MRD) assessment in early-stage cancer, but …

Circulating tumor DNA (ctDNA) sequencing holds considerable promise for early diagnosis
and detection of surveillance and minimal residual disease. Blood ctDNA monitors specific …